214 related articles for article (PubMed ID: 23602796)
1. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms.
Kwon H; Kang HC; Lee JH
Urology; 2013 Jun; 81(6):1325-9. PubMed ID: 23602796
[TBL] [Abstract][Full Text] [Related]
2. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome.
Park YW; Kim SB; Kwon H; Kang HC; Cho K; Lee KI; Kim YJ; Lee JH
Urology; 2013 Sep; 82(3):674-9. PubMed ID: 23850334
[TBL] [Abstract][Full Text] [Related]
3. Association of lower urinary tract symptom/benign prostatic hyperplasia measures with international index of erectile function 5 in middle-aged policemen of Korea and the role of metabolic syndrome and testosterone in their relationship.
Lee JH; Kwon H; Park YW
Urology; 2013 Nov; 82(5):1008-12. PubMed ID: 24041675
[TBL] [Abstract][Full Text] [Related]
4. Relationship between Metabolic Syndrome and Predictors for Clinical Benign Prostatic Hyperplasia Progression and International Prostate Symptom Score in Patients with Moderate to Severe Lower Urinary Tract Symptoms.
Zhao S; Chen C; Chen Z; Xia M; Tang J; Shao S; Yan Y
Urol J; 2016 Jun; 13(3):2717-26. PubMed ID: 27351328
[TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms.
De Nunzio C; Cindolo L; Gacci M; Pellegrini F; Carini M; Lombardo R; Franco G; Tubaro A
Urology; 2014 Nov; 84(5):1181-7. PubMed ID: 25443931
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation.
Gacci M; Vignozzi L; Sebastianelli A; Salvi M; Giannessi C; De Nunzio C; Tubaro A; Corona G; Rastrelli G; Santi R; Nesi G; Serni S; Carini M; Maggi M
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):101-6. PubMed ID: 23165431
[TBL] [Abstract][Full Text] [Related]
7. The Relationship between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Mean Platelet Volume: The Role of Metabolic Syndrome.
Zhao S; Tang J; Shao S; Yan Y
Urol Int; 2016; 96(4):449-58. PubMed ID: 26745140
[TBL] [Abstract][Full Text] [Related]
8. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.
Ozden C; Ozdal OL; Urgancioglu G; Koyuncu H; Gokkaya S; Memis A
Eur Urol; 2007 Jan; 51(1):199-203; discussion 204-6. PubMed ID: 16806666
[TBL] [Abstract][Full Text] [Related]
9. Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment.
Liao CH; Chung SD; Kuo HC
Urology; 2011 Dec; 78(6):1373-8. PubMed ID: 21962879
[TBL] [Abstract][Full Text] [Related]
10. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
11. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.
Lee JH; Kim Y; Park YW; Lee DG
J Sex Med; 2014 May; 11(5):1309-15. PubMed ID: 24612680
[TBL] [Abstract][Full Text] [Related]
12. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia.
Hong SK; Lee ST; Jeong SJ; Byun SS; Hong YK; Park DS; Hong JY; Son JH; Kim C; Jang SH; Lee SE
BJU Int; 2010 May; 105(10):1424-8. PubMed ID: 19874305
[TBL] [Abstract][Full Text] [Related]
13. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
14. Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study.
Lewandowski J; Sinski M; Symonides B; Korecki J; Rogowski K; Judycki J; Sieczych A; Możeńska O; Gaciong Z
Urology; 2013 Sep; 82(3):660-5. PubMed ID: 23987161
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
16. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
[TBL] [Abstract][Full Text] [Related]
17. Correlation between lipid profile and heme oxygenase system in patients with benign prostatic hyperplasia.
Vanella L; Russo GI; Cimino S; Fragalà E; Favilla V; Li Volti G; Barbagallo I; Sorrenti V; Morgia G
Urology; 2014 Jun; 83(6):1444.e7-13. PubMed ID: 24862399
[TBL] [Abstract][Full Text] [Related]
18. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
[TBL] [Abstract][Full Text] [Related]
19. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
[TBL] [Abstract][Full Text] [Related]
20. Relationship of estimated glomerular filtration rate with lower urinary tract symptoms/benign prostatic hyperplasia measures in middle-aged men with moderate to severe lower urinary tract symptoms.
Lee JH; Kwon H; Park YW; Cho IC; Min SK
Urology; 2013 Dec; 82(6):1381-5. PubMed ID: 24063940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
